BACKGROUND-Loss of imprinting (LOI) is an epigenetic alteration involving loss of parental origin-specific expression at normally imprinted genes. A LOI for IGF2, a paracrine growth
The selective isolation of a sub-population of cells from a larger, mixed population is a critical preparatory process to many biomedical assays. Here, we present a new cell isolation platform with a unique set of advantages over existing devices. Our technology, termed Immiscible Filtration Assisted by Surface Tension, exploits physical phenomena associated with the microscale to establish fluidic barriers composed of immiscible liquids. By attaching magnetically-responsive particles to a target cell population via immunocapture, we can selectively transport this population across the immiscible barrier and into a separate aqueous solution. The high interfacial energy associated with the immiscible phase / aqueous phase boundaries prevents unwanted cells or other contaminants from inadvertently crossing the immiscible phase. We have demonstrated, using fluorescent particles, stromal cells, and whole blood as “background”, that we can successfully isolate ~70% of a target breast cancer cell population with an average purity of >80%. Increased purity was obtained by coupling two immiscible barriers in series, a modification that only slightly increases operational complexity. Furthermore, several samples can be processed in parallel batches in a near-instantaneous manner without the requirement of any washing, which can cause dilution (negative selection) or significant uncontrolled loss (positive selection) of target cells. Finally, cells were observed to remain viable and proliferative following traverse through the immiscible phase, indicating that this process is suitable for a variety of downstream assays, including those requiring intact living cells.
Prostate cancer (PCa) is typically found as a multifocal disease suggesting the potential for molecular defects within the morphologically normal tissue. The frequency and spatial extent of DNA methylation changes encompassing a potential field defect are unknown. A comparison of non-tumor-associated (NTA) prostate to histologically indistinguishable tumor-associated (TA) prostate tissues detected a distinct profile of DNA methylation alterations (0.2%) using genome-wide DNA arrays based on the Encyclopedia of DNA Elements 18 sequence that tile both gene-rich and poor regions. Hypomethylation (87%) occurred more frequently than hypermethylation (13%). Several of the most significantly altered loci (CAV1, EVX1, MCF2L, and FGF1) were then used as probes to map the extent of these DNA methylation changes in normal tissues from prostates containing cancer. In TA tissues, the extent of methylation was similar both adjacent (2 mm) and at a distance (>1 cm) from tumor foci. These loci were also able to distinguish NTA from TA tissues in a validation set of patient samples. These mapping studies indicate that a spatially widespread epigenetic defect occurs in the peripheral prostate tissues of men who have PCa that may be useful in the detection of this disease.
The quantification of mRNA is a ubiquitous and critical tool for understanding cellular mechanisms in cancer. While RT-PCR is often the endpoint, the success of the analysis depends not only on the PCR reaction, but also on an entire process flow linking living cells to the PCR endpoint. For cultured cells, this process flow includes the culture itself, cell lysis, mRNA extraction and purification, and RT-PCR. While much research has been targeted to streamlining and increasing throughput of the PCR process, the remainder of the process flow has largely been neglected. In this study, we link a new mechanism for purifying mRNA, Immiscible Filtration Assisted by Surface Tension (IFAST), with cell culture on a single platform. IFAST uses an immiscible liquid barrier (e.g., oil) to separate the cell culture / lysis region from an elution buffer. Using paramagnetic particles (PMPs) that selectively bind mRNA, we extracted mRNA from the lysate by using a magnet to draw the PMP-captured mRNA through the immiscible phase. This process, which takes only seconds, replaces multiple washing steps required by current mRNA isolation protocols, which typically take 15-60 minutes to complete. The simplicity of IFAST enables facile integration of culture and mRNA extraction on an easy-to-use chip that requires only a micropipette and magnet to operate. Once proof-of-concept was demonstrated with a single cell type, the platform was expanded to incorporate co-culture of two cell types, with breast cancer cells and stromal cells in separate compartments connected via diffusion ports to allow cytokine exchange. Each compartment has an IFAST device, such that mRNA can be collected independently from each side. RT-PCR expression levels from the integrated culture / IFAST platform had less variance than similar experiments with independent culture and mRNA purification components, possibly due to the elimination of error during transfer. mRNA purified with the integrated device had a yield and purity similar to “gold standard” kits. Breast cancer cells co-cultured with bone marrow stromal cells showed increased proliferation and morphological changes relative to breast cancer cells cultured alone. Additionally, mRNA extracted from these cells using the integrated device showed transcriptional changes consistent with estrogen response, even in hormone-independent conditions. We have developed a new platform linking compartmentalized cell co-culture with NA isolation. This technology simplifies and accelerates two processes ubiquitous in cancer biology, enabling the collection of additional endpoints with finite resources while reducing error associated with manipulation. Furthermore, co-cultures of breast cancer with stroma from a metastatic site induced proliferation and transcriptional signaling associated with pro-growth conditions, illustrating the utility of this platform for studying the metastatic microenvironment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4272. doi:1538-7445.AM2012-4272
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.